This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Thymosin alpha 1 acts via Toll-like receptors on myeloid and plasmacytoid dendritic cells, triggering signaling pathways that increase immune-related cytokine production and improve immune cell subsets, indicating its potential to treat immune suppression in various diseases.
Why it matters
Understanding how thymosin alpha 1 modulates immune cells can guide development of therapies for immune suppression caused by aging, infections, or cancer, potentially improving patient outcomes.
How the study worked
This article summarizes extensive preclinical and clinical studies investigating thymosin alpha 1’s effects on immune cell subsets and immune function across different disease models and conditions.
What this study cannot tell us
The review does not specify the strength or design details of the included studies, limiting assessment of the robustness of the evidence.
Read the original research
Immune Modulation with Thymosin Alpha 1 Treatment.
Vitamins and hormones, 102, 151-78
Citation
King, R; Tuthill, C. (2016). Immune Modulation with Thymosin Alpha 1 Treatment.. Vitamins and hormones, 102, 151-78. https://doi.org/10.1016/bs.vh.2016.04.003